Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Samuel I MannDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.ORCID 0000-0003-3392-3170
Zhi LinDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.
Sophia K TanDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.ORCID 0000-0002-6181-7810
Jiaqi ZhuDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0002-5336-310X
Zachary X W WidelDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0003-3550-4498
Ian BakanasDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.
Jarrett P ManserghDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.
Rui LiuDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.
Mark J S KellyDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.ORCID 0000-0003-3209-1018
Yibing WuDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.
James A WellsDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.ORCID 0000-0001-8267-5519
Michael J TherienDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0003-4876-0036
William F DeGradoDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94158-9001, United States.ORCID 0000-0003-4745-263X
Funding
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targetsR01CA248323 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2020 to 2026
$2.6M
A 600 MHz NMR console and cryoprobe for studies of macromolecules, drug discovery and cancer biomarkersS10OD023455 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GROSS, JOHN D · 2018 to 2018
$820k
De novo design of functional metallocofactor-binding proteinsR00GM143529 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Samuel I Mann · 2024 to 2026
$747k
De novo design of functional metallocofactor-binding proteinsK99GM143529 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MANN, SAMUEL I · 2021 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
De Novo Design of Proteins That Bind Naphthalenediimides, Powerful Photooxidants with Tunable Photophysical Properties. · full record | OpenQuestion